EBSEmergent BioSolutions Inc.
Is the price fair?
Undemanding: modest expectations priced in and cheap against its own history.
Priced for a decline (~−18% a year). Little growth is priced in even as revenue fell 10% a year over three years, potential value, or a value trap.
Cheap vs its own history: P/E 13.4 vs a 23.6 median over 26 quarters (−43% vs median).
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What EBS's price assumes
- Free cash flow yield
- 27%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −18%
Growth the price implies · The price pays for −18% free cash flow growth a year for a decade; revenue has shrunk 10% a year over the last three.
- Price / book
- 1.27
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 1.27
- EV / EBIToperating margin −8.6%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $86M
- Market capitalisation51.3 million shares, counted Jul 30, 2026
- $320M
- 3-year revenue growth
- −10%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.
Drug Manufacturers, Specialty & Generic
Ranks #28 of 39 by RyuScore